Testing a new oral drug for radiation proctitis
Part of Digestive system clinical trials.
This trial tests an oral drug called Teslanbaicin for people who have pelvic cancer and developed radiation proctitis (inflammation of the rectum from radiation therapy). The goal is to see if it is safe and helps heal the inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with pelvic cancer and received radiation therapy that caused mild to moderate inflammation in your rectum.
- You are 18 years or older and willing to follow the study plan.
- Your blood counts and kidney/liver function are within acceptable ranges as checked by your doctor.
- Your expected survival is at least 6 months, and you are generally active (able to care for yourself).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new radioactive drug (161Tb-SibuDAB) for men with metastatic prostate cancer that has grown despite standard treatments. It aims to find the right dose and see if it can shrink tumors.
This study tests a new oral tablet (HRS-7525) for men with advanced prostate cancer that has spread. It aims to see if the drug is safe and effective, and may offer a new treatment option for those who have not responded to standard therapies.
This trial tests whether a special dietary supplement can help protect the rectum from radiation damage during chemoradiation for locally advanced rectal cancer. If it works, it may reduce painful bowel symptoms like frequent stools and cramping.
This trial tests a new drug (SI-B036) for people with advanced urological tumors or other solid tumors that have spread. The goal is to see if the drug is safe and effective, and it might help shrink tumors or slow their growth.
This Phase 2 study tests whether a shorter course of radiation, combined with chemotherapy (CAPOX) and an immunotherapy drug (tislelizumab), can control middle and low rectal cancer. It may also help people who strongly want to keep their anus, if the cancer and overall health fit the study rules.
This trial tests a new approach for people with locally advanced rectal cancer that has high-risk features. It combines short-course radiation with chemotherapy (CapeOX) and the immunotherapy drug toripalimab, with or without another drug called surufatinib, before surgery. The goal is to see if adding these drugs helps shrink the tumor and improve outcomes.
Hear when a new Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.